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Breast cancer survival in the USA has continually improved over the last six decades and has largely been accredited to
the use of mammography, advanced surgical procedures, and adjuvant therapies. Data indicate, however, that there were
substantial improvements in survival in the USA even prior to these technological and diagnostic advances, suggesting important
opportunities for early detection and treatment in low- and middle-income countries where these options are often unavailable
and/or unaﬀordable. Thus, while continuing to strive for increased access to more advanced technology, improving survival in
these settings should be more immediately achievable through increased awareness of breast cancer and of the potential for
successful treatment, a high-quality primary care system without economic or cultural barriers to access, and a well-functioning
referral system for basic surgical and hormonal treatment.
1.Introduction
Breast cancer is a leading cause of death and disability
among women, especially young women, in low- and
middle-income countries [1]. Though incidence and overall
mortality rates continue to be lower than in most high-
income countries, case fatality rates from breast cancer are
veryhigh.These highcase fatalityrates arelikelyduetoalack
of awareness of the beneﬁts of detection and treatment and a
scarcity of adequate facilities for detection and diagnosis, as
well as poor access to primary treatment.
Remarkable improvements have been achieved in the
probability of survival for women diagnosed with breast
cancer in the USA as compared to 60 years ago [2]. Early
detection through the use of mammography, high-quality
surgery, and adjuvant therapies including chemotherapy
and targeted therapies, such as hormonal therapy and,
more recently the HER2-directed agent trastuzumab, can be
credited for much of the recent improvement in outcome for
women with breast cancer in the USA. However, even prior
totheroutineuseofmammography oradjuvanttherapy,sig-
niﬁcant improvements were made in breast cancer survival,
and these can be traced to relatively low-cost interventions
that are still in use in high-income countries. Understanding
which healthcare interventions were available and how they
resulted in improvementsin the probabilityof survival could
be important, especially for designing programs in resource-
constrained settings where breast cancer case fatality is
high and many of the most costly and technology-intensive
diagnostic and therapeutic options are not available.
2.Breast CancerinLow-and
Middle-Income Countries
In many developing countries, the incidence of breast cancer
is now rising sharply due to changes in reproductive factors,
lifestyle, and increased life expectancy. Today, more than half
of incident cases occur in the developing world [14, 15].
Combined with still high case-fatality rates, this means that
mortality from breast cancer is a leading cause of death2 Journal of Oncology
Table 1: Stage of initial diagnosis of breast cancer for a selection of low- and middle-income countries and USA [3].
Region Country and city %S t a g eI /
localized
% Stage III-IV/
regional-metastatic Year (s) Source of data
Latin America
Mexico [4] 14 48 2002 Registry of the Mexican Social
Security Institute
Peru, Lima [5] 9 49 1985–1997 Instituto Nacional de Enfermedades
Neoplasicas
Brazil,[5]
Sao Paulo 10 67 1979–1989 Academic Hospital of the University
of Sao Paulo
Puerto Alegre 16 30 1975–1997 Academic Hospital of the Fed.
U n i v e r s i t yo fR i oG r a n d ed oS u l
Asia
India: [6, 7]
Mumbai 8 35 1995 Tata MemorialHospital Registry
Trivandrum 4 53 1996 Hospital Cancer Registry Trivandrum
Middle East
Saudi Arabia [8]∗ 24 62 2004 National Cancer Registry
Jordan, Amman [9]∗∗ 23 37 2008 Jordan Cancer Registry
Egypt, Gharbia [7, 10]∗ 26 74 2000–2002 Tanta Cancer Registry
Egypt, South [11] 11 50 2001–2008 South Egypt Cancer Institute
Africa
South Africa [12]
Blacks 5 78 1970–1987; Grote Schuur, Cape town;
Whites 31 31 1976–1997∗∗∗
Provincial Hospitals of Port Elizabeth
and East London,and Johannesburg
General Hospital
North America United States [13] 60 38 1999–2005 National cancer registry
∗For these countries data were not provided by stage (I, II, III, IV) and were given only as localized versus regional or distant metastatic.
∗∗The Jordan Cancer Registry for 2008 ﬁgures are 3% in-situ, 23% Stage I, 29% Stage II, 23% Stage III, 14% Stage IV, and 7.5% unknown.
∗∗∗Data collected from 4 hospitals, three from the ﬁrst-time period listed and the fourth from the second-time period listed.
among adult women in developing countries, as well as in
thedevelopedworld. In Mexico,forexample, breast canceris
now the second leading cause of death among women aged
30 to 54 and the leading cause of tumor-related death among
adult women of all ages [16].
The high probability of dying from breast cancer—the
case fatality rate, which is approximated by the ratio of
mortality to income—across the developing world further
reﬂects the inequities in early detection and access to
treatment [1, 17] .T h en u m b e ro fd e a t h sa sap e r c e n t a g eo f
incident cases in 2008 was 48% in low-income, 40% in low-
middle-income, and 38% in high-middle-income countries,
while it was 24% in high-income countries according to the
most recent Globocan/IARC data [18].
Available evidence on stage at diagnosis, though scarce,
indicate that a very high proportion of cases in the develop-
ing world are detected in late stages [1, 3]. (Table 1)I nm a n y
underserved populations, a majority of women present with
advanceddisease;theﬁgureisashighas78%inblackwomen
in South Africa. In contrast, in theUnited States the majority
of cases are detected in localized stages of the disease (Stages
I and II), a third is regionally advanced (Stage III), and only
5% are distant-stage metastatic (Stage IV) [13].
Many reasons are given for the advanced stage at
presentation and resultant poor survival rates in low- and
middle-incomecountries:thestigmaofbreastcancerandthe
associated societal implications of its treatments (especially
mastectomy) discourage women from seeking care early on;
lack of knowledge about breast health; scant options for
early detection due to limited access to routine care and
examinations; and lack of access to mammography and to
aﬀordable, high-quality treatment options.
3.OpportunitiestoImprove Breast
CancerOutcomesforWomenin
Developing Countries
In the short term, mammography and other expensive and
technologically complicated resources and therapies will not
likely be available to many of the world’s women. Though
we must continue to work at all levels to bring diagnostics
and therapeutics with a proven impact on outcomes to
these women as soon as possible, there are ways closer at
hand to improve the immediate outlook for women in these
settings.
Figure 1 shows the incidence and mortality rates for
breast cancer in the USA between 1940 and 2000. From
the late 1940s, breast cancer incidence rose steadily. By
contrast, mortality rates did not rise appreciably during this
period. Thus mortality-to-incidence ratios decreased dra-
matically, even before the generalized use of mammography
or adjuvant chemotherapy and antiestrogen therapy that
commenced in the mid- to late 1970s.Journal of Oncology 3
Table 2: Mortality/incidence ratios for breast cancer in the USA between 1950 and 1975.
Year Incidence/100,000 Mortality/100,000 Mortality/incidence ratio
1950 66·62 8 0 ·42
1955 64·92 9 ·80 ·46
1960 73 28·30 ·39
1965 82·92 8 ·50 ·34
1970 84·42 7 ·40 ·32
1975 119·23 1 ·60 ·27
Based on the Connecticut SEER database.
Table 2 presents the ratio of mortality over incidence,
as an approximation of the case-fatality rate, in 5-year
increments between 1950 and 1975. Between 1950 and
1975incidencenearly doubled,increasing from66.6/100,000
womento119.2/100,000,while mortality remained relatively
constant, 28/100,000 and 31.6/100,000, respectively. Thus,
during this time period, the ratio of mortality over incidence
(an approximation of the case-fatality rate) fell from 0.42
to 0.27 representing a 36% decline: This suggests that more
women were surviving their cancers in 1975 as compared
to 1950 and is true for both whites and blacks [19].
Further, the reduction in case-fatality rates is at least as
large as the improvement evidenced since the introduction
of mammography and adjuvant therapy. These ﬁndings
suggest considerable room for reducing the high mortality-
to-incidence ratio found in many developing countries even
without mammography or adjuvant therapy.
4.Explaining Improved Breast Cancer Survival
Ratesinthe USA Priorto 1975
The increases in incidence and survival for breast cancer in
the USAbetween 1950and 1975cannot be attributed only to
detection of in situ cancers that would not have progressed.
The proportion of in situ cases in known-stage cases in
the Connecticut Tumor Registry in that period was very
small and increased from only 0.3% in 1950–1954 to 1.9%
in 1970–1974, and it was largely unaﬀected by improved
reporting and a reduction in unknown-stage tumors. Thus,
the reduction in the mortality-to-incidence ratio must
largely reﬂect outcomes for patients with invasive cancers.
From1940to1970,thestagedistributionofreportedcasesin
Connecticut improved substantially. Regional and advanced
stages fell from 58% to 54% between 1940–1944 and 1950–
1954, and to 45% in 1970–1974 [20].
The period from 1940 to 1974 was a time in the USA
when evidence-based medicine became more widespread,
and healthcare became more generally available, including
increased use of routine gynecologic and general physical
examination. Cancer and the human breast also became
acceptabletopicsofconversation.Forexample,theAmerican
Cancer Society began promoting self-examination for breast
cancer in 1950 [21] and routine screening by cervical cytol-
ogy starting in 1952 [22]. Further, the era of oral contracep-
tivesinthe1960scontributedtogreaterinteractions between
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Figure 1: Breast cancer incidence and mortality, USA, 1940–2000.
healthy women and their healthcare providers. Authors
who analyzed data prior to 1974 assign the improvements
in survival to more eﬀective breast education programs,
increased breast cancer awareness, detection of tumors
palpable with self or breast-clinical examination, and better
diagnostics [19, 20]. Thus, the increase in survival rates in
the USA prior to 1975 strongly suggests potential to improve
breastcanceroutcomesindevelopingcountriesmorequickly
than we will be able to make routine mammography and
adjuvant therapy available.
Recent studies, showing breast physical examination and
breast self-examination to be unhelpful in reducing stage at
diagnosis [23–26], have considered only developedcountries
or urbanized areas of developing countries where routine
healthcare is generally available, breast cancer awareness and
education are high, and mammography is more routinely
accessible. These data, and hence the ﬁndings, are likely
to be less applicable to a population where breast cancer
education and awareness are low, access to the healthcare
system severely restricted, and the vast majority of patients
present with advanced disease.
5.Next Stepsto Improve Breast CancerSurvival
inLow-and Middle-Income Countries
While reducing the incidence of breast cancer is an ideal
goal, the options for achieving this are limited and longer
term, particularly for the developingworld. Healthy lifestyle,4 Journal of Oncology
including limiting alcohol consumption, maintenance of
ideal body weight, regular physical activity, and avoidance
of postmenopausal hormone replacement therapy, can have
an important impact on breast cancer incidence [15, 27].
Every eﬀo r ts h o u l db em a d et ol i m i tt h e s er i s kf a c t o r s
and thus breast cancer risk. Yet, even with strong eﬀorts
aimed at prevention, the incidence of breast cancer is likely
to increase in most developing countries due to changes
in reproductive patterns including later ﬁrst pregnancies,
reductionsinparity,andshorterdurationoflactation;aswell
as, declines in physical activity and increased life expectancy.
Increasing survival rates should also be a priority. Earlier
detection and timely, adequate surgery would likely result
in substantial improvements in survival in much of the
developing world. Education about breast cancer, advocacy
around curability, and increased coverage of basic healthcare
includingskilled breast physical examinations couldproduce
improvement in survival rates as occurred in the USA
between 1950 and 1975.
Education eﬀorts need to address the reality that many
women, particularly those with less income and education,
may not seek care when they feel a breast mass, because
they are unaware of what it represents, are concerned
about the stigma of cancer and being rejected by their
community and their partners, fear the potential loss of
the breast, or believe there are no eﬀective therapies for
the disease especially if all the women they have known
with breast cancer died. HIV—a stigma-laden disease, that
if untreated is universally fatal—provides important lessons
[28]. These same issues prevented many patients with HIV
from seeking care. By contrast, it has been demonstrated
thatbycombiningeducation,withbetterandmoreaccessible
healthcare facilities, trained medical personnel, and eﬀective
therapy, patients do seek and comply with treatment and
beneﬁt from it [28–30].
The ability to provide adequate aﬀordable access to
physical exams by healthcare workers is not a trivial obstacle.
An essential ﬁrst element is the existence of a functioning
primary care system staﬀed by providers trusted by their
community. While many countries continue to battle with a
weak primary infrastructure, examples, such as the Oportu-
nidades program and Seguro Popular in Mexico and Partners
In Health in rural Africa and Haiti, provide important
lessons for strengthening primary healthcare including, and
often especially, interventions to improve the health of
women [16, 31, 32].
These interventions are essential parts of overall health
system strengthening and can help with the prevention and
treatment ofmany diseasesinadditiontobreastcancer.Clin-
ical breast exams do not need to be performed by physicians
or nurses. In settings where community healthcare workers
have learned to care for patients with diseases as complex
as HIV, multidrug resistant tuberculosis, and malaria, they
could be trained to eﬀectively perform breast exams.
Large-bore core needle biopsy is a reliable method
to obtain tissue for diagnosis and can be performed by
trained personal in relatively simple ambulatory settings.
Ultrasonography, widely available in developing countries,
can eﬀectively localize tumors for biopsy. Pathology services
must beavailabletoprocessthespecimens butcanbelocated
regionally or outsourced globally.
In many developing countries, surgery is available in
regional centers, although additional training of surgeons
in appropriate techniques may be needed, and women
will require ﬁnancial support and transportation. Where
radiation therapy is not available, as is the case in many low-
income countries, the surgery should be a mastectomy.
Given the high proportion of hormone receptor positive
cancers, tamoxifen can be eﬀectively combined with surgery.
Unlike many treatments for breast cancer, generic tamoxifen
is low cost, taken orally, and in the vast majority of patients
is well tolerated and does not generate unmanageable side
eﬀects or require additional medications or care to control
symptoms.
6.Conclusions
Options exist to greatly expand low-cost alternatives for
earlierdetectionandtreatmentofbreastcancerindeveloping
countries. Guidelines have been developed and have been
stratiﬁed according to the resources available in speciﬁc
countries and health systems [33–36]. Many of the basic
interventions focus on education, awareness building, the
health of women, and expanding capacity at the primary and
community healthcare levels,and thusand also contributeto
overall health system strengthening [37].
Education to improve breast health awareness, breast
self-examination, and clinicalbreast exam are relatively inex-
pensive and canbe incorporated into existing primary health
infrastructures. Surgery and hormone therapy based on
tamoxifen are cost eﬀective, especially with early detection,
and implementable in poor-resource settings. Focusing on
providing these interventions in locations where they do not
currently exist could dramatically improve survival.
In no way does this abrogate the responsibility to even-
tually provide resources such as mammography, adjuvant
chemotherapy, and advanced targeted therapies such as
trastuzumab in these settings. However, great beneﬁt can
emerge from basic breast cancer education and awareness,
integrating breast exams into primary healthcare infras-
tructure, and adequate surgery combined with tamoxifen.
Implementation of these interventions should proceed as
quickly as possible, while the more complex and costly
interventions, such as mammography, are being made
more available. The provision of better primary healthcare,
education, and better medical outcomes will provide a solid
foundation for reducing stigma and fear that will make more
eﬀective the introduction of complex technologies, such as
mammography or adjuvant therapy.
There is no reason not to immediately strive for the
implementation of basic interventions for breast cancer care
and control in all settings. It is, in fact, our obligation.
CompetingInterest Statement
All authors have completed the Uniﬁed Competing Interest
form at http://www.icmje.org/coi disclosure.pdf (availableJournal of Oncology 5
on request from the corresponding author) and declare that
all authors had: (1) no ﬁnancial support for the submitted
workfrom anyoneotherthantheiremployer,(2)noﬁnancial
relationships with commercial entities that might have an
interest in the submitted work, (3) no spouses, partners,
or children with relationships with commercial entities that
might have an interest in the submitted work, (4) no
nonﬁnancial interests that may be relevant to the submitted
work.
Acknowledgments
We gratefully acknowledge excellent research support from
Afsan Bhadelia and Amanda Berger and thank Lou Gon-
salves for assistance in locating historical data. We also
thank H´ ector Arreola and Oscar M´ endez for data analysis
supported by CONACyT Grant Project 85055 from the
National Council for Science and Technology of Mexico.
All authors contributed equally to literature searches, data
interpretation,andwriting. DatafromtheConnecticutSEER
and tumor registry for the USA, and from registries in 8
developingcountries, are presented.Dr. L. Shulman,medical
oncologist and Chief Medical Oﬃcer at the Dana-Farber
C a n c e rI n s t i t u t e( D F C I ) ,i st h eg u a r a n t o ro ft h ep a p e r .H e
performs clinical research in breast cancer (BC) at the DFCI
and with partners in developingcountries. Dr. W. Willett, an
epidemiologist and Chair of the Department of Nutrition at
the Harvard School of Public Health, conducts research on
riskfactorsforBCdevelopment.Dr.A.Sieversisanoncology
fellow at the DFCI with experience providing cancer care
in resource poor settings. Dr. F. Knaul is an economist and
directs the Harvard Global Equity Initiative and undertakes
research on cancer care delivery in developing countries. As
a women living with BC, she also leads T´ omatelo a Pecho
A.C.aprogramtoproduceanddisseminateevidenceonearly
detection and treatment of BC in Latin America. L. Shulman
is Co-chair of the Global Task Force on Expanded Access
to Cancer Care and Control in Developing Countries, and
Felicia Knaul leads the Task Force Secretariat.
References
[1] P. Porter, “”Westernizing” women’s risks? Breast cancer in
lower-income countries,” New England Journal of Medicine,
vol. 358, no. 3, pp. 213–216, 2008.
[2] http://www.cancer.org/.
[3] F .A.SloanandH.Gelband,Eds.,CancerControlOpportunities
in Low- and Middle-Income Countries, Institute of Medicine of
the National Academies, Washington,DC, USA, 2007.
[ 4 ]F .M .K n a u l ,H .A r r e o l a - O r n e l a s ,E .V e l ´ azquez, J. Dorantes,
O. M´ endez, and L. Avila-Burgos, “El costo de la atenci´ on
m´ edica del c´ ancer mamario:elcaso del Instituto Mexicano del
Seguro Social,”Salud P´ ublica de M´ exico, vol.51, supplement 2,
pp. s286–s295, 2009.
[5] G. Schwartsmann, “Breast cancer in South America: chal-
lenges to improve early detection and medical managementof
a public health program,” Journal of Clinical Oncology, vol. 19,
no. 18, pp. 118s–124s,2001.
[6] R. Chopra, “The indian scene,” Journal of Clinical Oncology,
vol. 19, supplement 1, pp. 106S–111S, 2001.
[7] P. Boyle andB.Levin,World Cancer Report2008, International
Agency for Research on Cancer, Lyon, France, 2008.
[8] Saudi Cancer Registry. Ministry of Health. Kingdom of
Saudi Arabia. Cancer Incidence Report Saudi Arabia, 2004,
http://www.emro.who.int/ncd/pdf/saa cancer registry 2004
.pdf.
[9] Jordan Cancer Registry, Non-Communicable Diseases
Directorate. Ministry of Health. The Hashemite Kingdom
of Jordan. Cancer Incidence in Jordan, 2008, http://
www.moh.gov.jo/MOH/Files/Publication/Jordan%20Cancer
%20Registry 2008%20Report 1.pdf.
[10] Gharbiah Population-based Cancer Registry (GPCR). Tanta,
Egypt.
[11] A. A. S. Salem, M. A. E. Salem, and H. Abbass, “Breast cancer:
surgery at the south egypt cancer institute,” Cancers,v o l .2 ,
no. 4, pp. 1771–1778, 2010.
[ 1 2 ]D .A .V o r o b i o f ,F .S i t a s ,a n dG .V o r o b i o f ,“ B r e a s tc a n c e r
incidence in South Africa,” Journal of Clinical Oncology,
vol. 19, no. 18, supplement, pp. 125s–127s, 2001.
[13] American Cancer Society, “Breast Cancer Facts & Figures
2009-2010. Atlanta, Ga, USA, American Cancer Society. SEER
Cancer Statistics Review, 1975–2006. Bethesda, Md, USA,
National Cancer Institute,” M. Horner, L. Ries, M. Krapcho,
N. Neyman, R. Aminou, and N. Howlader, Eds., 2009,
http://seer.cancer.gov/csr/1975 2006/.
[14] N. Beaulieu, D. Bloom, R. Bloom, and R. Stein, Breakaway:
The Global Burden of Cancer—Challenges and Opportunities,
The Economist Intelligence Unit, London,UK, 2009.
[15] T. A. Ngoma, “World Health Organization cancer priorities
in developing countries,” Annals of Oncology, vol. 17, no. 8,
pp. viii9–viii14, 2006.
[16] F. M. Knaul, G. Nigenda, R. Lozano, H. Arreola-Ornelas, A.
Langer, and J. Frenk, “Breast cancer in Mexico: a pressing
priority,” Reproductive Health Matters,vol.16,no.32,pp. 113–
123, 2008.
[ 1 7 ]P .F a r m e r ,J .F r e n k ,F .M .K n a u le ta l . ,“ E x p a n s i o no fc a n c e r
care and control in countries of low and middle income: a call
to action,”TheLancet,vol.376,no.9747,pp.1186–1193,2010.
[18] “Calculated from: GLOBOCAN 2008: Cancer Incidence
and Mortality Worldwide in 2008. World Health Orga-
nization: International Agency for Research on Cancer,”
http://globocan.iarc.fr/.
[ 1 9 ]I .J a t o i ,W .F .A n d e r s o n ,S .R .R a o ,a n dS .S .D e v e s a ,“ B r e a s t
cancer trends among black and white women in the United
States,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7836–
7841, 2005.
[20] J. Flannery and P. Sullivan, “Female breast cancer in
Connecticut—incidence, mortality, survival—1935–1975,”
Connecticut Health Bulletin, vol. 92, no. 1, pp. 4–9, 1978.
[21] American CancerSociety, “The missingmemberofthebreast-
cancer team: breast-self examination,” Cancer Journal for
Clinicians, vol. 1, pp. 30–31, 1950.
[22] American Cancer Society, “Keeping up with cancer: digests
from current literature of special importance in diagosis and
treatment,” Cancer Journal for Clinicians, vol. 2, pp. 38–45,
1952.
[23] D. B. Thomas, D. L. Gao, R. M. Ray et al., “Randomized trial
of breast self-examination in Shanghai: ﬁnal results,” Journal
of the National Cancer Institute,vol.94, no.19,pp. 1445–1457,
2002.
[ 2 4 ]V .F .S e m i g l a z o v ,V .M .M o i s e e n k o ,A .G .M a n i k h a se ta l . ,
“Interim results of a prospective randomized study of self-
examination for early detection of breast cancer,” Voprosy
Onkologii, vol. 45, no. 3, pp. 265–271, 1999.6 Journal of Oncology
[ 2 5 ]M .L .B r o w n ,S .J .G o l d i e ,G .D r a i s m a ,J .H a r f o r d ,a n dJ .
Lipscomb, “Health service interventions for cancer control
in developing countries,” in Disease Control Priorities in
Developing Countries, D. Jamison, J. Breman, A. Measham, G.
Alleyne, M. Claeson, and D. Evans, Eds., Oxford University
Press, New York, NY, USA, 2006.
[26] H. Vainio and F. Bianchini, Eds., Breast Cancer Screening,
IARC Press, Lyon, France, 2002.
[27] W. Willett, R. Tamimi, S. Hankinson, D. Hunter, and G.
Colditz, “Nongenetic factors in the causation of Breast
Cancer,” in Diseases of the Breast, J. R. Harris, M. E. Lippman,
K.C.Osborne,andM.Morrow,Eds.,pp. 248–290,Lippincott,
Williams,and Wilkens, Philadelphia, Pa, USA, 2009.
[28] CanTreat International, “Scaling up cancer diagnosis and
treatment in developing countries: what can we learn fromthe
HIV/AIDS epidemic?” Annals of Oncology, vol. 21, pp. 680–
682, 2010.
[29] T. R. Frieden, A. Teklehaimanot, S. Chideya, P. Farmer, J. Y.
Kim, and M. C. Raviglione, “A road map to control malaria,
tuberculosis, and human immunodeﬁciency virus/AIDS,”
Archives of Internal Medicine, vol. 169, no. 18, pp. 1650–1652,
2009.
[30] P. Farmer, “Presentation: delivering cancer care in resource-
limited settings: lessons from infectious diseases and primary
health care,” in Proceedings of the International Conference:
Breast Cancer in Developing Countries,H a r v a r dU n i v e r s i t y ,
2009, http://isites.harvard.edu/icb/icb.do?keyword=k62597.
[31] Secretar´ ıa de Desarrollo Social. Oportunidades. SEDESOL,
M´ exico, DF, http://www.oportunidades.gob.mx/Portal/.
[32] J. Frenk, “Bridging the divide: global lessons from evidence-
based health policy in Mexico,” Lancet, vol. 368, no. 9539,
pp. 954–961, 2006.
[33] B. O. Anderson, C.-H. Yip, R. A. Smith et al., “Guideline
implementation for breast healthcare in low-income and
middle-income countries: overview of the breast health global
initiative Global Summit 2007,” Cancer, vol. 113, no. 8,
supplement, pp. 2221–2243, 2008.
[34] D. Collingridge, “Delivering consensus from the Asian Oncol-
ogy Summit 2009,” The Lancet Oncology, vol. 10, no. 11,
pp. 1029–1030, 2009.
[35] B. Anderson and E. Cazap, “Breast health global initiative
(BHGI) outline for program development in Latin America,”
SaludP´ ublicadeM´ exico,vol.51,supplement2,pp.S309–S315,
2009.
[36] D.KerrandR.Midgley,“Canwetreatcancerforadollaraday?
Guidelinesforlow-incomecountries,” NewEngliand Journal of
Medicine, vol. 363, no. 9, pp. 801–803, 2010.
[37] Institute of Medicine, The US Commitment to Global Health:
Recommendations for the public and private sectors,T h e
National Academies Press, Washington,DC, USA, 2009.